Goldman Sachs’s Roivant Sciences ROIV Stock Holding History

Goldman Sachs’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100,600	Closed	-$1.06M	–	6030
2024 Q2	$1.06M	Buy	+100,600	New	+$1.1M	﹤0.01%	4387

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's ROIV Position: Q1 2026 in Review

Goldman Sachs increased its Roivant Sciences (ROIV) stake by 1.2% in Q1 2026, buying an estimated $3.31M and bringing the position to 11,111,591 shares worth $308M. The position accounts for 0.04% of the portfolio, ranked #493.

Goldman Sachs first reported a position in ROIV in Q1 2022 and has held it in 17 quarters since. 440 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Goldman Sachs held 11,111,591 shares of Roivant Sciences worth $308M as of Q1 2026.
Goldman Sachs bought 128,908 Roivant Sciences shares in Q1 2026, an estimated $3.31M.
Roivant Sciences made up 0.04% of Goldman Sachs's portfolio in Q1 2026, its #493 holding.
Goldman Sachs first reported a position in Roivant Sciences in Q1 2022 and has held it in 17 quarters since.
440 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.